Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Completed Phase 3 Interventional Results available

Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

NCT01795547
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole and aripiprazole once-monthly, Paliperidone and paliperidone palmitate
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Not applicable Interventional Results available

iTEST: Introspective Accuracy as a Novel Target for Functioning in Psychotic Disorders

NCT05899348
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Psychotic Disorders
Interventions
iTEST
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
La Jolla, California • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Phase 4 Interventional

Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

NCT00177008
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Social Anxiety Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2007 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Phase 4 Interventional

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

NCT00044187
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Bipolar Disorder
Interventions
Sibutramine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
16
States / cities
El Centro, California • Jacksonville, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Not applicable Interventional

Health Promotion and Fitness for Younger and Older Adults With SMI

NCT02090335
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
In SHAPE, Fitness Club Membership
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 18, 2026, 9:53 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

NCT05211947
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 51 Years
Enrollment
1,356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
49
States / cities
Anaheim, California • Bellflower, California • Culver City, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 18, 2026, 9:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

SPARK Healthy Sleep

NCT07119268
View directory record Official record
Conditions
Schizophrenia and Related Disorders, Sleep Disturbance
Interventions
SPARK Healthy Sleep
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia

NCT04013555
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
N-acetylcysteine (NAC), Placebo, Tryptophan
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Phase 4 Interventional Results available

Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia

NCT00455702
View directory record Official record
Conditions
Schizophrenia
Interventions
d-cycloserine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Not applicable Interventional Results available

Treatment to Enhance Cognition in Bipolar Disorder

NCT01470781
View directory record Official record
Conditions
Bipolar Disorder, Psychosis
Interventions
BrainWorks, Computer Control
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Not applicable Interventional

Effects of Motivating People With Schizophrenia to Exercise

NCT00559572
View directory record Official record
Conditions
Schizophrenia
Interventions
Motivational group sessions, Time and attention control group sessions
Behavioral · Other
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
22 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 18, 2026, 9:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Peripheral Immune System in Individuals With Schizophrenia

NCT05109065
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
SCID (Standardized Clinical Interview for DSM-V), PSS (Perceived Stress Score), Urine Toxicology Screen, Vitals, Blood Work, PQ-B, COVID Screening, Positive and Negative Syndrome Scale (PANSS)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Appeal and Impact of E-cigarettes in Smokers With SMI

NCT03050853
View directory record Official record
Conditions
Tobacco Dependence, Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
E-cigarette
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Louisville, Kentucky • Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

NCT00690170
View directory record Official record
Conditions
Healthy Subjects
Interventions
Ketamine, Nicotine, Placebo, Ketamine and Nicotine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Smoking Cessation for Veterans With Severe and Persistent Mental Illness

NCT00960375
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia, Affective Psychosis, Bipolar, Affective Disorders, Psychotic
Interventions
BTSCS, StSST
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Single Dose Intranasal Insulin On Cognitive Function

NCT00646581
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Placebo, Insulin (Humulin)
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 18, 2026, 9:53 PM EDT
Terminated Phase 3 Interventional

A Long-Term Safety Study of Pomaglumetad Methionil in Schizophrenia

NCT01487083
View directory record Official record
Conditions
Schizophrenia
Interventions
Pomaglumetad methionil
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
36
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Not applicable Interventional Results available

Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone

NCT00538642
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
ziprasidone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Not applicable Interventional

A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia

NCT00538070
View directory record Official record
Conditions
Schizophrenia
Interventions
Sarcosine
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

NCT00641745
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone HCl, Risperidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
41
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 18, 2026, 9:53 PM EDT
Not listed Not applicable Interventional

Multi-component Intervention for Diabetes in Adults With Serious Mental Illness

NCT03627377
View directory record Official record
Conditions
Schizophrenia, Obesity, Diabetes, Lifestyle Risk Reduction, Serious Mental Illness
Interventions
Multi-component Intervention for Diabetes in Adults with Serious Mental Illness
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 18, 2026, 9:53 PM EDT
Recruiting Phase 3 Interventional

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

NCT07184619
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Evenamide 15 mg bid, Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

NCT00139919
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 18, 2026, 9:53 PM EDT
Completed No phase listed Observational

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

NCT02050854
View directory record Official record
Conditions
Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Disorders
Interventions
Not listed
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Garden Grove, California • Atlanta, Georgia • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 18, 2026, 9:53 PM EDT